CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2019--
AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City.
Geoff MacKay, AVROBIO’s President and Chief Executive Officer, will provide an overview of the Company and a business update. A live webcast of the presentation will also be available on the investors section of the AVROBIO company website at www.avrobio.com. After the live webcast, the event will remain archived on the AVROBIO website for 90 days.
About AVROBIO, Inc.
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005183/en/
Source: AVROBIO, Inc.
Christopher F. Brinzey
Westwicke, an ICR Company
The Yates Network